Table 3.
Univariable and multivariable models to predict grade 2 or higher adverse events
|
|
Odds ratio
|
95%CI
|
P value
|
| Univariable model: | |||
| PLR (> 300) | 0.40 | (0.16, 0.98) | 0.044 |
| NLR (> 5) | 0.58 | (0.31, 1.10) | 0.097 |
| Steroid use | 2.74 | (1.62, 4.64) | < 0.001 |
| Antibiotics use | 1.02 | (0.52, 1.98) | 0.954 |
| Treatment | |||
| PD-1 CLTA-4 | 3 | (1.35, 6.67) | 0.007 |
| PD-1 TKI | 4 | (1.71, 9.34) | 0.001 |
| Other1 | 4 | (0.55, 28.97) | 0.170 |
| Multivariable model: | |||
| PLR (> 300) | 0.26 | (0.09, 0.74) | 0.011 |
| Steroid use | 4.43 | (2.21, 8.88) | < 0.001 |
| Treatment | |||
| PD-1/CLTA-4 | 2.57 | (1.06, 6.24) | 0.037 |
| PD-1/TKI | 3.39 | (1.34, 8.56) | 0.01 |
| Other1 | 3.50 | (0.21, 57.86) | 0.381 |
1
Other include single agent cytotoxic t-lymphocyte antigen-4 and other immune checkpoint inhibitors/tyrosine kinase inhibitor combinations. CI: Confidence interval; PLR: Platelet-lymphocyte ratio; NLR: Neutrophil-lymphocyte ratio; PD-1: Programmed cell death ligand 1; CLTA-4: Cytotoxic t-lymphocyte antigen-4; TKI: Tyrosine kinase inhibitor.